{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:59:54Z","timestamp":1774522794533,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00228-025-03839-1","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T02:34:01Z","timestamp":1743906841000},"page":"853-862","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A novel physiologically-based pharmacokinetic model to estimate reduced CYP3A4 activity in cancer patients utilizing the neutrophil-to-lymphocyte ratio as an inflammatory marker"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6291-5623","authenticated-orcid":false,"given":"David E.","family":"Coutant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5049-1018","authenticated-orcid":false,"given":"Jessica","family":"Rehmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7130-4755","authenticated-orcid":false,"given":"Donna M.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen D.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"key":"3839_CR1","doi-asserted-by":"crossref","unstructured":"Morgan E (2017) Regulation of drug-metabolizing enzymes and drug metabolism by inflammatory responses. In: Xie W (Ed.). Drug metabolism in diseasesed. Academic Press","DOI":"10.1016\/B978-0-12-802949-7.00002-X"},{"issue":"5","key":"3839_CR2","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/cpt.1115","volume":"104","author":"R Evers","year":"2018","unstructured":"Evers R, Piquette-Miller M, Polli JW, Russel FGM, Sprowl JA, Tohyama K, Ware JA, de Wildt SN, Xie W, Brouwer KLR (2018) Disease-Associated changes in drug transporters may impact the pharmacokinetics and\/or toxicity of drugs: a white paper from the international transporter consortium. Clin Pharmacol Ther 104(5):900\u2013915. https:\/\/doi.org\/10.1002\/cpt.1115","journal-title":"Clin Pharmacol Ther"},{"key":"3839_CR3","doi-asserted-by":"crossref","unstructured":"Liu L, Evers R, Montgomery D (2020) Protein drug-drug interactions for therapeutic proteins. In: Ma S, Chowdhury, SK (Ed.) Identification and quantification of drugs, metabolites, drug metabolizing enzymes, and transporters ed. Elsevier, pp 387-416","DOI":"10.1016\/B978-0-12-820018-6.00013-2"},{"issue":"6","key":"3839_CR4","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/cpt.2814","volume":"113","author":"DE Coutant","year":"2023","unstructured":"Coutant DE, Boulton DW, Dahal UP, Deslandes A, Grimaldi C, Pereira JNS, S\u00e4ll C, Sarvaiya H, Schiller H, Tai G, Umehara K, Yuan Y, Dallas S (2023) Therapeutic protein drug interactions: a white paper from the international consortium for innovation and quality in pharmaceutical development. Clin Pharmacol Ther 113(6):1185\u20131198. https:\/\/doi.org\/10.1002\/cpt.2814","journal-title":"Clin Pharmacol Ther"},{"key":"3839_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/B978-0-12-802949-7.00002-X","volume-title":"Drug metabolism in diseasesed","author":"E Morgan","year":"2017","unstructured":"Morgan E (2017) Regulation of drug-metabolizing enzymes and drug metabolism by inflammatory responses. In: Xie W (ed) Drug metabolism in diseasesed. Academic Press, pp 21\u201358"},{"issue":"10","key":"3839_CR6","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00228-012-1266-x","volume":"68","author":"T Naito","year":"2012","unstructured":"Naito T, Tashiro M, Yamamoto K, Ohnishi K, Kagawa Y, Kawakami J (2012) Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients. Eur J Clin Pharmacol 68(10):1411\u20131418. https:\/\/doi.org\/10.1007\/s00228-012-1266-x","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"3839_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/psp4.12003","volume":"4","author":"Y Xu","year":"2015","unstructured":"Xu Y, Hijazi Y, Wolf A, Wu B, Sun YN, Zhu M (2015) Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity. CPT Pharmacometrics Syst Pharmacol 4(9):507\u2013515. https:\/\/doi.org\/10.1002\/psp4.12003","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"3839_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cpt.128","volume":"98","author":"DE Coutant","year":"2015","unstructured":"Coutant DE, Kulanthaivel P, Turner PK, Bell RL, Baldwin J, Wijayawardana SR, Pitou C, Hall SD (2015) Understanding disease-drug interactions in cancer patients: implications for dosing within the therapeutic window. Clin Pharmacol Ther 98(1):76\u201386. https:\/\/doi.org\/10.1002\/cpt.128","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"3839_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1124\/dmd.116.073585","volume":"45","author":"HJ Einolf","year":"2017","unstructured":"Einolf HJ, Zhou J, Won C, Wang L, Rebello S (2017) A physiologically-based pharmacokinetic modeling approach to predict drug-drug interactions of Sonidegib (LDE225) with perpetrators of CYP3A in cancer patients. Drug Metab Dispos 45(4):361\u2013374. https:\/\/doi.org\/10.1124\/dmd.116.073585","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"3839_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/cpt.917","volume":"103","author":"E Schwenger","year":"2018","unstructured":"Schwenger E, Reddy VP, Moorthy G, Sharma P, Tomkinson H, Masson E, Vishwanathan K (2018) Harnessing meta-analysis to refine an oncology patient population for physiology-based pharmacokinetic modeling of drugs. Clin Pharmacol Ther 103(2):271\u2013280. https:\/\/doi.org\/10.1002\/cpt.917","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"3839_CR11","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/jcph.1377","volume":"59","author":"MJ Sorich","year":"2019","unstructured":"Sorich MJ, Mutlib F, van Dyk M, Hopkins AM, Polasek TM, Marshall JC, Rodrigues AD, Rowland A (2019) Use of physiologically based pharmacokinetic modeling to identify physiological and molecular characteristics driving variability in Axitinib exposure: a fresh approach to precision dosing in oncology. J Clin Pharmacol 59(6):872\u2013879. https:\/\/doi.org\/10.1002\/jcph.1377","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"3839_CR12","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/clpt.2013.79","volume":"94","author":"KK Machavaram","year":"2013","unstructured":"Machavaram KK, Almond LM, Rostami-Hodjegan A, Gardner I, Jamei M, Tay S, Wong S, Joshi A, Kenny JR (2013) A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6. Clin Pharmacol Ther 94(2):260\u2013268. https:\/\/doi.org\/10.1038\/clpt.2013.79","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3839_CR13","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1208\/s12248-016-9890-5","volume":"18","author":"X Jiang","year":"2016","unstructured":"Jiang X, Zhuang Y, Xu Z, Wang W, Zhou H (2016) Development of a physiologically based pharmacokinetic model to predict disease-mediated therapeutic protein-drug interactions: modulation of multiple cytochrome P450 enzymes by interleukin-6. AAPS J 18(3):767\u2013776. https:\/\/doi.org\/10.1208\/s12248-016-9890-5","journal-title":"AAPS J"},{"issue":"9","key":"3839_CR14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1124\/dmd.119.090092","volume":"48","author":"PK Turner","year":"2020","unstructured":"Turner PK, Hall SD, Chapman SC, Rehmel JL, Royalty JE, Guo Y, Kulanthaivel P (2020) Abemaciclib does not have a clinically meaningful effect on pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 substrates in patients with cancer. Drug Metab Dispos 48(9):796\u2013803. https:\/\/doi.org\/10.1124\/dmd.119.090092","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"3839_CR15","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/jcla.21908","volume":"30","author":"R Mercan","year":"2016","unstructured":"Mercan R, Bitik B, Tufan A, Bozbulut UB, Atas N, Ozturk MA, Haznedaroglu S, Goker B (2016) The association between neutrophil\/lymphocyte ratio and disease activity in rheumatoid arthritis and Ankylosing Sspondylitis. J Clin Lab Anal 30(5):597\u2013601. https:\/\/doi.org\/10.1002\/jcla.21908","journal-title":"J Clin Lab Anal"},{"issue":"7","key":"3839_CR16","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.ajem.2019.11.030","volume":"38","author":"T Takada","year":"2020","unstructured":"Takada T, Hoogland J, Yano T, Fujii K, Fujiishi R, Miyashita J, Takeshima T, Hayashi M, Azuma T, Moons KGM (2020) Added value of inflammatory markers to vital signs to predict mortality in patients suspected of severe infection. Am J Emerg Med 38(7):1389\u20131395. https:\/\/doi.org\/10.1016\/j.ajem.2019.11.030","journal-title":"Am J Emerg Med"},{"issue":"1","key":"3839_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5005\/jp-journals-10071-24074","volume":"26","author":"S Babu","year":"2022","unstructured":"Babu S, Pulicken M, Thazhathuveedu AK (2022) Peripheral blood neutrophil-to-lymphocyte ratio as a predictor of functional outcomes in patients with hemorrhagic stroke. Indian J Crit Care Med 26(1):18\u201322. https:\/\/doi.org\/10.5005\/jp-journals-10071-24074","journal-title":"Indian J Crit Care Med"},{"issue":"1","key":"3839_CR18","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1186\/s12879-022-07535-8","volume":"22","author":"F Subhani","year":"2022","unstructured":"Subhani F, Chhotani AA, Waheed S, Zahid RO, Azizi K, Buksh AR (2022) Development of COVID-19 severity assessment score in adults presenting with COVID-19 to the emergency department. BMC Infect Dis 22(1):576. https:\/\/doi.org\/10.1186\/s12879-022-07535-8","journal-title":"BMC Infect Dis"},{"issue":"1","key":"3839_CR19","doi-asserted-by":"publisher","first-page":"e13037","DOI":"10.1111\/eci.13037","volume":"49","author":"GL Erre","year":"2019","unstructured":"Erre GL, Paliogiannis P, Castagna F, Mangoni AA, Carru C, Passiu G, Zinellu A (2019) Meta-analysis of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in rheumatoid arthritis. Eur J Clin Invest 49(1):e13037. https:\/\/doi.org\/10.1111\/eci.13037","journal-title":"Eur J Clin Invest"},{"issue":"17","key":"3839_CR20","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1016\/j.ejca.2011.03.028","volume":"47","author":"MJ Proctor","year":"2011","unstructured":"Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O\u2019Reilly DS, Foulis AK, Horgan PG, McMillan DC (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow inflammation outcome study. Eur J Cancer 47(17):2633\u20132641. https:\/\/doi.org\/10.1016\/j.ejca.2011.03.028","journal-title":"Eur J Cancer"},{"key":"3839_CR21","doi-asserted-by":"publisher","unstructured":"Yamamoto T, Kawada K, Obama K (2021) Inflammation-related biomarkers for the prediction of prognosis in colorectal cancer patients. Int J Mol Sci 22(15). https:\/\/doi.org\/10.3390\/ijms22158002","DOI":"10.3390\/ijms22158002"},{"issue":"5","key":"3839_CR22","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/clpt.2011.35","volume":"89","author":"C Schmitt","year":"2011","unstructured":"Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S (2011) Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther 89(5):735\u2013740. https:\/\/doi.org\/10.1038\/clpt.2011.35","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3839_CR23","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/cpt.1596","volume":"107","author":"Y Guo","year":"2020","unstructured":"Guo Y, Lucksiri A, Dickinson GL, Vuppalanchi RK, Hilligoss JK, Hall SD (2020) Quantitative prediction of CYP3A4- and CYP3A5-mediated drug interactions. Clin Pharmacol Ther 107(1):246\u2013256. https:\/\/doi.org\/10.1002\/cpt.1596","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3839_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/bdd.1830","volume":"34","author":"S Cheeti","year":"2013","unstructured":"Cheeti S, Budha NR, Rajan S, Dresser MJ, Jin JY (2013) A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. Biopharm Drug Dispos 34(3):141\u2013154. https:\/\/doi.org\/10.1002\/bdd.1830","journal-title":"Biopharm Drug Dispos"},{"issue":"5","key":"3839_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/psp4.12289","volume":"7","author":"V Pilla Reddy","year":"2018","unstructured":"Pilla Reddy V, Walker M, Sharma P, Ballard P, Vishwanathan K (2018) Development, verification, and prediction of osimertinib drug-drug interactions using PBPK modeling approach to inform drug label. CPT Pharmacometrics Syst Pharmacol 7(5):321\u2013330. https:\/\/doi.org\/10.1002\/psp4.12289","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"3839_CR26","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/S0090-4295(01)01405-4","volume":"58","author":"SF Shariat","year":"2001","unstructured":"Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM (2001) Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 58(6):1008\u20131015","journal-title":"Urology"},{"issue":"4","key":"3839_CR27","first-page":"312","volume":"15","author":"S Iwase","year":"2004","unstructured":"Iwase S, Murakami T, Saito Y, Nakagawa K (2004) Steep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia in cancer patients. Eur Cytokine Netw 15(4):312\u2013316","journal-title":"Eur Cytokine Netw"},{"issue":"13","key":"3839_CR28","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1200\/jco.2011.38.9346","volume":"30","author":"JR Infante","year":"2012","unstructured":"Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, Fingert H, Pierce KJ, Xu H, Roberts WG, Shreeve SM, Burris HA, Siu LL (2012) Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol 30(13):1527\u20131533. https:\/\/doi.org\/10.1200\/jco.2011.38.9346","journal-title":"J Clin Oncol"},{"issue":"8","key":"3839_CR29","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1111\/bcp.13259","volume":"83","author":"LG Franken","year":"2017","unstructured":"Franken LG, Masman AD, de Winter BCM, Baar FPM, Tibboel D, van Gelder T, Koch BCP, Mathot RAA (2017) Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect? Br J Clin Pharmacol 83(8):1701\u20131712. https:\/\/doi.org\/10.1111\/bcp.13259","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"3839_CR30","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/bcp.13459","volume":"84","author":"JM Brussee","year":"2018","unstructured":"Brussee JM, Vet NJ, Krekels EHJ, Valkenburg AJ, Jacqz-Aigrain E, van Gerven JMA, Swart EL, van den Anker JN, Tibboel D, de Hoog M, de Wildt SN, Knibbe CAJ (2018) Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure. Br J Clin Pharmacol 84(2):358\u2013368. https:\/\/doi.org\/10.1111\/bcp.13459","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3839_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1164\/rccm.201510-2114OC","volume":"194","author":"NJ Vet","year":"2016","unstructured":"Vet NJ, Brussee JM, de Hoog M, Mooij MG, Verlaat CW, Jerchel IS, van Schaik RH, Koch BC, Tibboel D, Knibbe CA, de Wildt SN (2016) Inflammation and organ failure severely affect Midazolam clearance in critically Ill children. Am J Respir Crit Care Med 194(1):58\u201366. https:\/\/doi.org\/10.1164\/rccm.201510-2114OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"3839_CR32","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/jcph.1093","volume":"58","author":"DE Coutant","year":"2018","unstructured":"Coutant DE, Hall SD (2018) Disease-drug interactions in inflammatory states via effects on CYP-mediated drug clearance. J Clin Pharmacol 58(7):849\u2013863. https:\/\/doi.org\/10.1002\/jcph.1093","journal-title":"J Clin Pharmacol"},{"key":"3839_CR33","doi-asserted-by":"publisher","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B, Vera-Badillo FE, Aneja P, Oca\u00f1a A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors a systematic review and meta-analysis. J Natl Cancer Inst 106 (6):dju124. https:\/\/doi.org\/10.1093\/jnci\/dju124","DOI":"10.1093\/jnci\/dju124"},{"issue":"5","key":"3839_CR34","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/1520-6017(200105)90:5<638::AID-JPS1020>3.0.CO;2-L","volume":"90","author":"PM Bertilsson","year":"2001","unstructured":"Bertilsson PM, Olsson P, Magnusson KE (2001) Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cells. J Pharm Sci 90(5):638\u2013646","journal-title":"J Pharm Sci"},{"issue":"8","key":"3839_CR35","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/ajg.2013.151","volume":"108","author":"B Mor\u00f3n","year":"2013","unstructured":"Mor\u00f3n B, Verma AK, Das P, Taavela J, Dafik L, Diraimondo TR, Albertelli MA, Kraemer T, M\u00e4ki M, Khosla C, Rogler G, Makharia GK (2013) CYP3A4-catalyzed simvastatin metabolism as a non-invasive marker of small intestinal health in celiac disease. Am J Gastroenterol 108(8):1344\u20131351. https:\/\/doi.org\/10.1038\/ajg.2013.151","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"3839_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s0009-9236(96)90022-3","volume":"59","author":"CC Lang","year":"1996","unstructured":"Lang CC, Brown RM, Kinirons MT, Deathridge MA, Guengerich FP, Kelleher D, O\u2019Briain DS, Ghishan FK, Wood AJ (1996) Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism. Clin Pharmacol Ther 59(1):41\u201346. https:\/\/doi.org\/10.1016\/s0009-9236(96)90022-3","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03839-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03839-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03839-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:59:24Z","timestamp":1747205964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03839-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3839"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03839-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent to participate was obtained from all parents or guardians of individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"DEC, JR, and SDH were employees and shareholders of Eli Lilly and Company at time of writing. DME was an employee of the University of Michigan at time of writing.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Employment"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}